. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Inflammopharmacology. 2014 Aug 19;22(5):295–303. doi: 10.1007/s10787-014-0214-z

Table 1. Demographic and descriptive data of subjects.

In patients with MS, two non-naïve subjects were on no disease-modifying therapy (DMT) Of the naïve, subjects, 3 were on DMTs (Rebif, Avonex.)